Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Rev Neurol (Paris) ; 178(4): 306-314, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-34895744

RESUMEN

As part of the non-criteria clinical manifestations, postural orthostatic tachycardia syndrome (POTS), a multisystem autonomic dysfunction, can co-exist with antiphospholipid syndrome (APS). Several pieces of evidence hint on the autoimmune basis of POTS, and its possible association with several autoimmune diseases, including APS. Indeed, the evidence exists in the etiologies, symptomatology, and treatment options. Although infections, viral ones in particular, stress, and pregnancy are etiologies to both POTS and APS, the exact pathophysiological connection is still to be studied taking into consideration the activity of cytokines in both diseases. Nevertheless, certain immunomodulatory treatments used for the catastrophic or obstetrical forms of APS, such as intravenous immunoglobulins (IVIG) and steroids, have been also used for the treatment of POTS resistant to classical treatments. Therefore, our review aims to highlight the association between POTS and APS, shedding light on the common etiologies explaining the pathophysiology of the two disorders, the diagnostic approach to POTS as a possible clinical criterion of APS, and the treatment of APS in the context of treating POTS.


Asunto(s)
Síndrome Antifosfolípido , Enfermedades Autoinmunes , Síndrome de Taquicardia Postural Ortostática , Disautonomías Primarias , Síndrome Antifosfolípido/complicaciones , Síndrome Antifosfolípido/diagnóstico , Síndrome Antifosfolípido/terapia , Enfermedades Autoinmunes/complicaciones , Femenino , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Síndrome de Taquicardia Postural Ortostática/diagnóstico , Síndrome de Taquicardia Postural Ortostática/epidemiología , Síndrome de Taquicardia Postural Ortostática/etiología , Embarazo
2.
Lupus ; 29(3): 225-235, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31933408

RESUMEN

Chronic inflammation has profound tumor-promoting effects. Inflammatory cells are the key players in immunosurveillance against tumors, and immunosuppression is known to increase the risk of tumors. Autoimmune diseases, which manifest as loss of self-tolerance and chronic immune dysregulation, provide a perfect environment for tumor development. Aside from managing the direct inflammatory consequences of autoimmune pathogenesis, cancer risk profiles should be considered as a part of a patient's treatment. In this review, we describe the various associations of malignancies with autoimmune diseases, specifically systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and Sjögren's syndrome, as well as discuss the mechanisms contributing to the pathogenesis of both disorders.


Asunto(s)
Enfermedades del Tejido Conjuntivo/complicaciones , Neoplasias Hematológicas/etiología , Enfermedades Autoinmunes/complicaciones , Enfermedades del Tejido Conjuntivo/fisiopatología , Neoplasias Hematológicas/fisiopatología , Humanos , Inflamación/complicaciones , Inflamación/fisiopatología , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/fisiopatología , Enfermedades Reumáticas/complicaciones , Enfermedades Reumáticas/fisiopatología , Factores de Riesgo , Esclerodermia Sistémica/complicaciones , Esclerodermia Sistémica/fisiopatología , Síndrome de Sjögren/complicaciones , Síndrome de Sjögren/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...